No Data
No Data
Market Underestimates Kiniksa Pharmaceuticals' Abiprubart Potential Despite Positive Industry Indicators
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
PDF Version HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of A
Express News | Wells Fargo Initiates Coverage On Kiniksa Pharmaceuticals With Overweight Rating, Announces Price Target of $34
Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan
Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $30
Express News | Kiniksa Pharmaceuticals Ltd : JP Morgan Raises Target Price to $30 From $26